Under what clinical conditions should spironolactone be held (e.g., hyperkalemia, acute kidney injury, eGFR < 30 mL/min/1.73 m², significant rise in creatinine, volume depletion, hypotension, pregnancy, or initiation of other potassium‑raising agents)?

When to Hold Spironolactone

Stop spironolactone immediately if potassium rises to ≥6.0 mEq/L or if creatinine rises to >310 μmol/L (3.5 mg/dL), and monitor blood chemistry closely with specific treatment as needed. 1

Critical Thresholds for Discontinuation

Severe Hyperkalemia (≥6.0 mEq/L)

• Immediately discontinue spironolactone when serum potassium reaches or exceeds 6.0 mEq/L 1
• Monitor blood chemistry closely and initiate specific treatment for hyperkalemia 1
• The FDA label confirms hyperkalemia risk increases with impaired renal function and concomitant use of potassium-raising agents 2

Severe Renal Dysfunction

• Stop spironolactone immediately when creatinine rises to >310 μmol/L (3.5 mg/dL) 1
• Monitor blood chemistry closely as specific treatment of renal dysfunction may be needed 1
• The drug is substantially excreted by the kidney, increasing risk of adverse reactions with impaired renal function 2

Dose Reduction Thresholds (Rather Than Complete Discontinuation)

Moderate Hyperkalemia (>5.5 mEq/L but <6.0 mEq/L)

• Halve the dose of spironolactone (e.g., from 25 mg daily to 25 mg on alternate days) when potassium rises to >5.5 mEq/L 1
• Monitor blood chemistry closely after dose reduction 1

Moderate Renal Dysfunction

• Halve the dose when creatinine rises to >220 μmol/L (2.5 mg/dL) 1
• Monitor blood chemistry closely after dose adjustment 1

Contraindications to Initiation (Do Not Start)

Baseline Laboratory Values

• Do not initiate if baseline potassium is ≥5.0 mEq/L 1
• Do not initiate if creatinine is >2.5 mg/dL in men or >2.0 mg/dL in women 1
• Do not initiate if eGFR is <30 mL/min/1.73 m² 1
• The 2022 ACC/AHA/HFSA guidelines classify inappropriate use with these parameters as potentially harmful (Class III: Harm) 1

Clinical Conditions

• Avoid in pregnancy due to antiandrogenic effects and potential for adversely affecting male sex differentiation during embryogenesis 2
• Use extreme caution in patients with hepatic disease with cirrhosis and ascites, as sudden alterations in fluid and electrolyte balance may precipitate hepatic encephalopathy and coma; initiate only in hospital setting 2

Temporary Holds (Situational)

Volume Depletion and Acute Illness

• Temporarily hold during episodes of diarrhea causing dehydration, as this increases hyperkalemia risk 1
• Consider temporary hold during acute dehydration or volume depletion to prevent symptomatic hypotension and worsening renal function 2
• The FDA label warns that excessive diuresis may cause symptomatic dehydration, hypotension, and worsening renal function 2

Loop Diuretic Interruption

• Consider temporary hold if loop diuretic therapy is interrupted due to worsening renal function or hyperkalemia 1
• Development of worsening renal function or hyperkalemia often reflects acute clinical change requiring careful evaluation of the entire medical regimen 1

High-Risk Situations Requiring Enhanced Monitoring (Not Necessarily Discontinuation)

Patient Characteristics

• Elderly patients are at higher risk for hyperkalemia and worsening renal function, requiring closer monitoring 1
• Diabetic patients, particularly those requiring insulin, have increased hyperkalemia risk 1, 3
• Patients with baseline renal insufficiency require more frequent monitoring 1, 2

Medication Interactions

• Concomitant ACEI or ARB use increases hyperkalemia risk, though this combination is often necessary for heart failure management 1, 3
• Avoid NSAIDs and COX-2 inhibitors as they increase hyperkalemia risk 1
• Discontinue or reduce potassium supplements when initiating spironolactone 1
• Higher doses of ACEIs (captopril ≥75 mg daily; enalapril or lisinopril ≥10 mg daily) increase hyperkalemia risk 1

Monitoring Schedule After Adverse Events

• Check potassium and renal function within 3 days and at 1 week after any dose adjustment or clinical change 1
• Continue monitoring at least monthly for the first 3 months 1
• More frequent monitoring is needed when spironolactone is given with other drugs that cause hyperkalemia or in patients with impaired renal function 2

Common Pitfalls to Avoid

Do not permanently discontinue spironolactone for mild hyperkalemia (5.0-5.5 mEq/L) without first attempting dose reduction and addressing reversible causes 1. Secondary analyses of RALES and EMPHASIS-HF showed that despite potassium levels >5.5 mEq/L, spironolactone maintained benefits 1.

Do not down-titrate or discontinue renin-angiotensin-aldosterone inhibitors to manage chronic hyperkalemia, as these drugs improve outcomes in heart failure and proteinuric kidney disease 4. Instead, use potassium binders or other conservative measures to maintain these beneficial medications 1, 5.

Do not assume all hyperkalemia is drug-related—evaluate for other causes including acute clinical deterioration, worsening heart failure, or progressive kidney disease 1.